Behavior Therapy and Sibutramine for the Treatment of Adolescent Obesity: A Randomized Controlled Trial | Adolescent Medicine | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Trioano RP, Flegal KM, Kuczmarski RJ, Campbell SM, Johnson CL. Overweight prevalence and trends for children and adolescents: the national health and examination survey, 1963 to 1991.  Arch Pediatr Adolesc Med.1995;149:1085-1091.Google Scholar
2.
 Overweight Among US Children and Adolescents: National Health and Nutrition Examination Survey Data Briefs.  Hyattsville, Md: National Center for Health Statistics; 2002. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed March 14, 2003.
3.
Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000.  JAMA.2002;288:1728-1732.Google Scholar
4.
Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased evidence of non-insulin dependent diabetes among Japanese schoolchildren correlates with an increased intake of animal protein and fat.  Clin Pediatr (Phila).1998;37:111-115.Google Scholar
5.
Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study.  N Engl J Med.1992;327:1350-1355.Google Scholar
6.
Pinhas-Hamiel O, Dolan LM, Daniels SR.  et al.  Increased incidence of non-insulin-dependent diabetes mellitus among adolescents.  J Pediatr.1996;128:608-615.Google Scholar
7.
Glaser NS. Non-insulin dependent diabetes mellitus in Mexican-American children.  West J Med.1998;168:11-16.Google Scholar
8.
Dietz WH. Pharmacotherapy for childhood obesity? maybe for some.  Obes Res.1994;2:54-55.Google Scholar
9.
Neufeld ND, Raffel LJ, Landon C, Chen YD, Vadheim CM. Early presentation of type 2 diabetes in Mexican-American youth.  Diabetes Care.1998;21:80-86.Google Scholar
10.
Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth.  Diabetes Care.1999;22:345-354.Google Scholar
11.
Phillips DIW, Young JB. Birth weight, climate at birth and the risk of obesity in adult life.  Int J Obes Relat Metab Disord.2000;24:281-287.Google Scholar
12.
Haddock CK, Shadish WR, Klesges RC, Stein RJ. Treatments for childhood and adolescent obesity.  Ann Behav Med.1994;16:235-244.Google Scholar
13.
Robinson TN. Behavioral treatment of childhood and adolescent obesity.  Int J Obes.1999;23(suppl 12):S52-S57.Google Scholar
14.
Goldfield GS, Raynor HA, Epstein LH. Treatment of pediatric obesity. In: Wadden TA, Stunkard AJ, eds. Handbook of Obesity Treatment. New York, NY: Guilford Press; 2002:532-556.
15.
Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine.  Obes Res.1996;4:263-270.Google Scholar
16.
Lean MEJ. Sibutramine: a review of clinical efficacy.  Int J Obes.1997;21(suppl 1):S30-S36.Google Scholar
17.
Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity.  Obes Res.1998;6:1-11.Google Scholar
18.
Hansen DL, Toubro S, Stock MJ, MacDonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction.  Int J Obes Relat Metab Disord.1999;23:1016-1024.Google Scholar
19.
Hollander PA, Elbein SC, Hirsch IR.  et al.  Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study.  Diabetes Care.1998;21:1288-1294.Google Scholar
20.
Sjostrom L, Rissanen A, Andersen T.  et al. for the Multicentre Orlistat Study Group.  Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.  Lancet.1998;352:167-172.Google Scholar
21.
Davidson MH, Hauptman J, DiGirolamo M.  et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.  JAMA.1999;281:235-242.Google Scholar
22.
Hill JO, Hauptman J, Anderson JW.  et al.  Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.  Am J Clin Nutr.1999;69:1108-1116.Google Scholar
23.
 Meridia (sibutramine hydrochloride) [package insert]. North Chicago, Ill: Abbott Laboratories; 2002.
24.
Wadden TA, Stunkard AJ, Rich L.  et al.  Obesity in black adolescent girls: a controlled clinical trial by diet, behavior modification, and parental support.  Pediatrics.1990;85:345-352.Google Scholar
25.
Wadden TA, Berkowitz RI. Weight Reduction and Pride (WRAP) Program: Teens' Edition. Philadelphia: University of Pennsylvania; 2001.
26.
Wadden TA, Berkowitz RI. Weight Reduction and Pride (WRAP) Program: Parents' EditionPhiladelphia: University of Pennsylvania; 2001.
27.
Calloway CW, Chumlea WC, Bouchard C. Circumferences. In: Lohman TC, Roche AR, Martorell R, eds. Anthropometric Standardization Manual. Champaign, Ill: Human Kinetics Publishers; 1988:39-64.
28.
Stunkard AJ, Messick S. The Three-Factor Eating Questionnaire to measure dietary restraint, disinhibition and hunger.  J Psychosom Res.1985;29:71-83.Google Scholar
29.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1998.
30.
 Epi Info 2002. Database & Statistics Software for Public Health Professionals.  Atlanta, Ga: Epidemiology Program Office at Centers for Disease Control and Prevention; 2002.
31.
Haffner SM, Kennedy E, Gonzalez C, Stein MP, Miettinen H. A prospective analysis of the HOMA model: The Mexico City Diabetes Study.  Diabetes Care.1996;19:1138-1141.Google Scholar
32.
Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski Not Available, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity.  Arch Intern Med.2001;161:218-227.Google Scholar
33.
Phelan S, Wadden TA. Combining behavioral and pharmacologic treatment for obesity.  Obes Res.2002;10:560-574.Google Scholar
34.
James WP, Astrup A, Finer N.  et al.  Effect of sibutramine on weight maintenance after weight loss: a randomized trial.  Lancet.2000;356:2119-2125.Google Scholar
35.
Wadden TA, Osei S. The treatment of obesity: an overview. In: Wadden TA, Stunkard AJ, eds. Handbook of Obesity Treatment. New York, NY: Guilford Press; 2002:229-248.
36.
Leibel RL, Rosenblaum M, Hirsh J. Changes in energy expenditure resulting from altered body weight.  N Engl J Med.1995;332:621-628.Google Scholar
37.
Smith DE, Wing RR. Diminished weight loss and behavioral compliance during repeated diets in obese patients with type II diabetes.  Health Psychol.1991;10:378-383.Google Scholar
38.
 Committee for Proprietary Medicinal Products Opinion Following an Article 31 Referral: Sibutramine . London, England: The European Agency for the Evaluation of Medicinal Products; 2002. Available at: http://www.emea.eu.int/pdfs/human/referral/451402en.pdf. Accessibility verified March 14, 2003.
39.
American Diabetes Association.  Type 2 diabetes in children and adolescents.  Pediatrics.2000;105:671-680.Google Scholar
40.
Wadden TA, Anderson DA, Foster GD. Two-year changes in lipids and lipoprotiens associated with the maintenance in a 5% to 10% reduction in initial weight: some findings and some questions.  Obes Res.1999;7:170-178.Google Scholar
41.
Wadden TA, Berkowitz RI, Vogt RA, Steen SN, Stunkard AJ. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.  Obes Res.1997;5:218-226.Google Scholar
Original Contribution
April 9, 2003

Behavior Therapy and Sibutramine for the Treatment of Adolescent Obesity: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Department of Psychiatry, Weight and Eating Disorders Program, University of Pennsylvania School of Medicine, Philadelphia (Drs Berkowitz and Wadden, and Ms Cronquist); and Departments of Psychiatry (Dr Berkowitz) and Pediatrics (Dr Tershakovec), The Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia.

JAMA. 2003;289(14):1805-1812. doi:10.1001/jama.289.14.1805
Abstract

Context Adolescent obesity is becoming a national public health problem. Weight-loss medications including sibutramine facilitate weight control in adults and could be used with obese adolescents in combination with behavior therapy (BT).

Objective To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program.

Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial consisting of 82 adolescents aged 13 to 17 years with a body mass index (BMI) of 32 to 44 conducted from March 1999 to August 2002 at a university-based clinic for 6 months, followed by open-label treatment during months 7 to 12.

Interventions For the first 6 months, participants received either BT and sibutramine or BT and placebo. From months 7 to 12, all participants received sibutramine in open-label treatment.

Main Outcome Measures Percentage change in BMI; systolic and diastolic blood pressure and pulse; and hunger.

Results In intention-to-treat analysis at month 6, participants in the BT and sibutramine group lost a mean (SD) of 7.8 kg (6.3 kg) and had an 8.5% (6.8%) reduction in BMI, which was significantly more than weight loss of 3.2 kg (6.1 kg) and reduction in BMI of 4.0% (5.4%) in the BT and placebo group. Significantly greater reductions in hunger (P = .002) also were reported by participants who received BT and sibutramine. From months 7 to 12, adolescents initially treated with sibutramine gained 0.8 kg (10.5 kg) with continued use of the medication, whereas those who switched from placebo to sibutramine lost an additional 1.3 kg (5.4 kg). Medication dose was reduced (n = 23) or discontinued (n = 10) to manage increases in blood pressure, pulse rate, or other symptoms.

Conclusions The addition of sibutramine to a comprehensive behavioral program induced significantly more weight loss than did BT and placebo. Until more extensive safety and efficacy data are available, medications for weight loss should be used only on an experimental basis in adolescents and children.

×